New Weight-Loss drug candidate begins human testing in china
NCT ID NCT07294235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called BGM1812 in 60 healthy or overweight/obese Chinese adults who do not have diabetes. The main goal is to check the drug's safety and how the body processes it. Participants receive either the drug or a placebo by injection, and researchers monitor side effects and measure drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Yunnan University of Chinese Medicine
RECRUITINGKunming, Yunnan, 650000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection help tackle obesity and diabetes? a safety trial begins
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
- App sends mindfulness exercises right after weight regain to keep dieters on track
- Sleep program aims to reduce pregnancy risks in african american women
- Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
- Weekly shot could help shed pounds in obesity trial